SS-31 (Elamipretide) – User Manual & Dosage Protocol Guide

SS-31, also known as Elamipretide, is a mitochondria-targeted tetrapeptide studied for its ability to support mitochondrial membrane integrity and cellular energy production in research settings.

SS-31 is designed to selectively target cardiolipin within the inner mitochondrial membrane.

Research Applications

• Mitochondrial bioenergetics research
• ATP production studies
• Oxidative stress models
• Cardiovascular function research
• Skeletal muscle performance models
• Neuroprotection investigations

Disclaimer: SS-31 is for research and experimental use only in this context. While Elamipretide has undergone clinical investigation, it is not broadly FDA-approved for general therapeutic use.

Lyophilized Powder

Freeze-dried SS-31 for reconstitution

Pre-Reconstituted Solution

Injectable research preparation

Availability and concentration vary by supplier.

SS-31 is studied for its ability to:

• Target and bind cardiolipin in the inner mitochondrial membrane
• Stabilize mitochondrial structure
• Reduce excessive reactive oxygen species (ROS) production
• Improve electron transport chain efficiency
• Support ATP synthesis in experimental models

Effects are primarily evaluated in preclinical and clinical investigational research.

There is no approved general-use dosage outside regulated clinical protocols. The following reflects common research patterns only.

Injectable Research Model

Subcutaneous (SC) Administration

Typical range: 2–5 mg

Frequency: Once daily

Notes: Common mitochondrial research range

Investigational Range

Typical range: 5–10 mg

Frequency: Once daily

Notes: Used in higher-demand bioenergetic models

Dosing in human clinical studies has often been weight-based, though investigational protocols vary.

Human equivalent dosing must follow structured clinical calculations.

Initiation Phase

Duration: 1–2 weeks

Purpose: Tolerance and mitochondrial response evaluation

Active Study Phase

Duration: 4–12 weeks

Purpose: Bioenergetic and performance observation

Rest Period

Duration: 2–4 weeks

Purpose: Washout between study cycles

Cycle duration varies based on research endpoints.

Supplies

• Sterile bacteriostatic water
• Sterile syringe
• Alcohol swabs

General Procedure

1. Clean vial stopper with alcohol.
2. Add bacteriostatic water to desired concentration.

• Example: 10 mg vial + 2 mL → 5 mg/mL

1. Swirl gently to dissolve (do not shake).
2. Refrigerate at 2–8°C after reconstitution.
3. Use within 2–4 weeks or per research protocol.

Avoid excessive agitation to preserve peptide integrity.

Subcutaneous Injection Model

• Common sites: abdomen, thigh
• Clean site prior to administration
• Inject slowly
• Rotate injection sites

Some research protocols evaluate timing relative to exercise or metabolic stress exposure.

Lyophilized Powder

Storage: Cool, dry environment

Shelf life: Up to 12 months

Reconstituted Solution

Storage: Refrigerated (2–8°C)

Shelf life: 2–4 weeks

Protect From:

Light, heat, and contamination

Discard if the solution becomes cloudy or discolored.

• Not for unsupervised therapeutic application
• Human safety outside controlled clinical settings is not established
• Possible research observations may include:
• Injection-site irritation
• Mild headache
• Temporary fatigue
• Transient nausea

Clinical trials have reported generally favorable tolerability, but long-term data is still under investigation.

Maintain sterile handling techniques at all times.

Keep out of reach of children.

Peptide: SS-31 (Elamipretide)
Category: Mitochondrial Research / Bioenergetics
Delivery: Subcutaneous research model
Typical Investigational Range: 2–10 mg daily
Cycle: 4–12 week research designs
Storage: Refrigerated after reconstitution